The Division of Translational Medicine (DTM) comprises about 150 motivated and creative translational researchers who share the common goal of understanding human biology and pathophysiology relevant to the improvement of regional health care by improving diagnosis, disease prevention, therapeutic applications, and implementation of advanced therapies.
The DTM team aims to expedite the transformation of new research discoveries into clinical applications and conversely emphasize the discovery of new biological concepts through direct patient-based observation that could stimulate new research developments. The DTM team will use cutting edge technologies to empower translational scientists and clinicians for new discoveries, engaging clinicians and patients in research, building collaborative networks, and training a new generation of clinical and translational scientists within the region.
The DTM will implement an integrated strategy by converging clinical, laboratory and bioinformatics scientists expertise to reduce redundancy and increase cost effectiveness while enhance crossbreeding of ideas and scientific collaboration. Initially, the DTM will focus on the characterization of human genetics, epigenetic, meta-genomics, proteomics, metabolomics, and disease phenotyping using high-throughput multiplex assays, integrating and interrogating dense data sets using system biology approach and advanced computational techniques in direct collaboration with the Division of Biomedical Informatics, the Division of Epidemiology, the Division of Experimental Genomics and the Division of Experimental Biology.
Division Development Focus
- Build the state-of-art biomedical research infrastructure to serve the scientific and clinical community at Sidra and in Qatar
- Provide centralized resources that enable scientists and clinician to conduct cutting edge biomedical research.
- Build a strong and coherent scientific team that is productive, goal oriented, harmonized and capable of rapidly gaining international recognition.
- Build national and international collaborative networks to enhance the impact of local scientific activities.
- Develop, implement and study advanced therapies beyond standard care.
Division Core Values
- Create an integrated scientific team inclusive of biomedical research, computational biology and clinical studies.
- Apply system biology to characterize the functional impact of variability in genetic, epigenetic, metagenomic, proteomic and metabolic signatures under biological and pathophysiological conditions.
- Develop new therapeutic intervention, including cell and gene therapy.
Core laboratories which will serve the research and clinic needs
Tissue management core: responsible for all clinical sample collection (blood, tissue, body fluids, and fecal samples), purification, aliquoting, barcoding, storage, tracking, inventory, distribution and annual bio-repository report.
Genomic Core (Research and Clinical): responsible for high throughput data generation in CLIA compliant environment, providing services for gene expression, micro RNA profiling, CNV screen, target validation, WGS, WES, RNAseq, none coding RNAseq, Chipseq, microbiomeseq.
Proteomic and metabolic core: serum protein and metabolic MS analysis
Deep phenotyping Core: 16 color FACS analysis, cell sorting and cytokine profiling.
Tissue-cell-gene therapy GMP facility: Development and production of cell therapy, gene therapy reagents for clinical use
Single cell network program: Immune monitor, treatment evaluation, drug functional screen.
Imagining core: development of new methods in Magnetic resonance imaging (MRI) and Magnetic Resonance Spectroscopy (MRS)
Chemical analytics core: Provide customized chemical analysis, biochemical synthesis and drug screen.
Translational Research program
Section of Human immunology, Tumor biology and tumor immunotherapy
- Characterization of immunome under immune perturbation
- Tumor Immunotherapy clinical study and trails
- Tumor molecular biology
Section of human Genetics
- Identify genetic variants unique for the GCC region
- Identify causal variants for genetic disorders
- Monogenic disorders
- Autosomal dominant
- Autosomal recessive
- X-link dominant
- X-link recessive
- Somatic mutations
- Multigenic disorders- structure variation, CNV, translocation, Indel, fusion genes.
- Multigenic risk factors
- Genetic penetrance analysis
- Population based homozygosis analysis
- Identification of mild phenotypes
Section of Maternal/fetal health
- Mechanisms of Pre term birth
- Mechanisms of infertility and in vitro fertilization
- Mechanisms of Spontaneous abortion
- None invasive prenatal genetic testing
Section of System biology (with Division of Medical Bioinformatics)
- Big data to knowledge development;
- Research and clinical data integration, interpretation, dada mining,
- Module development and
- Interactive data visualization.
Clinical Research Center (CRC)
- GMP facility for tissue, cell, gene and transplant therapy
- R&D for development and scale up of adoptive cell therapy products
- Clinical services: HLA typing, blood bank test, TTV lab, apheresis unit
- Conduct and management Clinical trials and clinical studies
- Clinical outcome programs
Analytical Research program
Section of Infectious Disease
- Hepatitis (B, C, E) prevention and mechanistic study
- Bacterial Co-infection
- Drug resistance study
- Vaccine development
Partners, Society & Agencies
- WCMC – genetic study of breast cancer and obesity, Qatar University animal facility access and collaboration
- Qatar Biomedical Institute – Genetic therapy, genetic medicine, computational biology
- Illumina, San Diego, California – Genome projects
- Jackson Laboratories, Bar Harbor, Main and Farmington, Connecticut – Animal models, genomic medicine
- NIH, Bethesda, Maryland
- Nodality, South San Francisco – Single Cell Network
- CHOP, Philadelphia, Pennsylvania – Children disorders
- CITN, Seattle, Washington – Advanced immunotherapy clinical trials
- CHI – Human immunology clinical studies
- Department of transfusion Medicine, CC – cellular therapy developments
- NCI – T cell engineer and reprograming
- San Raffaele Institute, Milan Italy – Gene therapy and bone marrow transplant